Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 3;62(6):3. doi: 10.1167/iovs.62.6.3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2021 The Authors

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

PMC Copyright notice

Figure 5. — Knockdown of endogenous ID3 enhances TGFβ2-induced IOP elevation. Intravitreal injection of Ad5 Null + Ad5-hTGFβ2 (n = 5) (OS) resulted in a significant elevation in IOP, on days 5 to 23 after injection, (P < 0.0001; 2-factor ANOVA) until day 28 (P < 0.05), compared with Ad5-mID3 shRNA + Ad5-null (n = 5), and Ad5-null + Ad5 null (n = 5) (OS) injected eyes. The IOP in Ad5-Null injected eyes (n = 5) (OS) was not significantly different from uninjected control eyes (OD) at any time point measured. Injection of Ad5-mID3 shRNA + Ad5-Null (n = 5) (OS) led to a more modest but still-significant increase in IOP that manifested from day 5 (P < 0.01) until day 22 (P < 0.0001) as compared with Ad5-null injected (n = 5) eyes (OS). Intravitreal injection of Ad5-mID3-shRNA + Ad5-hTGFβ2 (n = 5) (OS) enhanced the TGFβ2-mediated IOP elevation significantly at day 12 (P < 0.01) to day 22 (P < 0.0001). Error bars represent ± SEM.